SOPHiA GENETICS (NASDAQ:SOPH) CEO Sells 9,838 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.22, for a total value of $51,354.36. Following the transaction, the chief executive officer directly owned 670,651 shares in the company, valued at approximately $3,500,798.22. The trade was a 1.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Monday, June 22nd, Ross Muken sold 422 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.38, for a total value of $2,270.36.
• On Monday, April 20th, Ross Muken sold 760 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total value of $3,952.00.
• On Tuesday, April 14th, Ross Muken sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total value of $13,888.00.
• On Monday, April 13th, Ross Muken sold 4,442 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $21,143.92.
• On Friday, April 10th, Ross Muken sold 3,687 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.69, for a total value of $17,292.03.
• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,484.24.

SOPHiA GENETICS Stock Performance

Shares of SOPH traded up $0.10 during mid-day trading on Tuesday, reaching $5.44. 284,563 shares of the company’s stock were exchanged, compared to its average volume of 187,273. The business’s fifty day simple moving average is $5.12 and its 200-day simple moving average is $4.96. The stock has a market capitalization of $456.36 million, a PE ratio of -10.46 and a beta of 0.96. SOPHiA GENETICS SA has a 52-week low of $2.92 and a 52-week high of $6.30. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The business had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SOPH. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. BTIG Research restated a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $7.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Federated Hermes Inc. boosted its holdings in SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock valued at $682,000 after purchasing an additional 31,000 shares in the last quarter. Akre Capital Management LLC boosted its holdings in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Dimensional Fund Advisors LP increased its position in SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $49,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.